Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Francis X. McCormack, M.D.
University of Cincinnati
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University
Palo Alto, California, United States
- National Jewish Hospital
Denver, Colorado, United States
- Emory University
Atlanta, Georgia, United States
- Loyola University
Chicago, Illinois, United States
- Brigham and Woman'S Hospital
Boston, Massachusetts, United States
- University of Cincinnati
Cincinnati, Ohio, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Swedish Health
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jan 2018
- Primary completion
- 30 Jun 2025
- Completion
- 30 Jun 2025
- Last update posted
- 24 Dec 2024
- Registered enrollment
- 60
- Registry id
- NCT03150914
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.